MKKGY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of 15.36% compared to Merck KGaA's net margin of 15.91%. Merck KGaA's return on equity of 9.62% beat BioNTech SE's return on equity of -2.35%.

Merck KGaA has a consensus price target of $40.10, signalling upside risk potential of 33.62%. On the other hand BioNTech SE has an analysts' consensus of $136.02 which suggests that it could grow by 7.2%. Given that Merck KGaA has higher upside potential than BioNTech SE, analysts believe Merck KGaA is more attractive than BioNTech SE.

Merck KGaA has a beta of 1.009, which suggesting that the stock is 0.86599999999999% more volatile than S&P 500. In comparison BioNTech SE has a beta of 0.182, suggesting its less volatile than the S&P 500 by 81.764%.

Merck KGaA has a quarterly dividend of $0.47 per share corresponding to a yield of 1.57%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.06% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than BioNTech SE quarterly revenues of $1.4B. Merck KGaA's net income of $889.7M is higher than BioNTech SE's net income of $217.9M. Notably, Merck KGaA's price-to-earnings ratio is 22.28x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.87x versus 9.27x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of 15.36% compared to Merck KGaA's net margin of 68.44%. Merck KGaA's return on equity of 9.62% beat CureVac NV's return on equity of 21.3%.

Merck KGaA has a consensus price target of $40.10, signalling upside risk potential of 33.62%. On the other hand CureVac NV has an analysts' consensus of $7.30 which suggests that it could grow by 56.08%. Given that CureVac NV has higher upside potential than Merck KGaA, analysts believe CureVac NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 1.009, which suggesting that the stock is 0.86599999999999% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Merck KGaA has a quarterly dividend of $0.47 per share corresponding to a yield of 1.57%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.06% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than CureVac NV quarterly revenues of $543.2M. Merck KGaA's net income of $889.7M is higher than CureVac NV's net income of $371.8M. Notably, Merck KGaA's price-to-earnings ratio is 22.28x while CureVac NV's PE ratio is 8.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.87x versus 1.76x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of 15.36% compared to Merck KGaA's net margin of -14092.9%. Merck KGaA's return on equity of 9.62% beat InflaRx NV's return on equity of -61.55%.

Merck KGaA has a consensus price target of $40.10, signalling upside risk potential of 33.62%. On the other hand InflaRx NV has an analysts' consensus of -- which suggests that it could grow by 215.46%. Given that InflaRx NV has higher upside potential than Merck KGaA, analysts believe InflaRx NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 1.009, which suggesting that the stock is 0.86599999999999% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.657, suggesting its more volatile than the S&P 500 by 65.659%.

Merck KGaA has a quarterly dividend of $0.47 per share corresponding to a yield of 1.57%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.06% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than InflaRx NV quarterly revenues of $136.2K. Merck KGaA's net income of $889.7M is higher than InflaRx NV's net income of -$19.2M. Notably, Merck KGaA's price-to-earnings ratio is 22.28x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.87x versus 813.56x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of 15.36% compared to Merck KGaA's net margin of -16.95%. Merck KGaA's return on equity of 9.62% beat Immatics NV's return on equity of -16.88%.

Merck KGaA has a consensus price target of $40.10, signalling upside risk potential of 33.62%. On the other hand Immatics NV has an analysts' consensus of $16.42 which suggests that it could grow by 133.19%. Given that Immatics NV has higher upside potential than Merck KGaA, analysts believe Immatics NV is more attractive than Merck KGaA.

Merck KGaA has a beta of 1.009, which suggesting that the stock is 0.86599999999999% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.769%.

Merck KGaA has a quarterly dividend of $0.47 per share corresponding to a yield of 1.57%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 10.06% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck KGaA quarterly revenues are $5.8B, which are larger than Immatics NV quarterly revenues of $55.6M. Merck KGaA's net income of $889.7M is higher than Immatics NV's net income of -$9.4M. Notably, Merck KGaA's price-to-earnings ratio is 22.28x while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.87x versus 5.65x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.